Aurora Test for Patients Treated With Recombinant Gonadotropins

Inclusion Criteria: * Patients are between 22-38 years old * BMI between 17-33 * provide written informed consent * Patients undergoing a first or second ICSI treatment cycle. * Patients will be treated by ICSI (intracytoplasmic sperm injection) * Patients agree that the oocytes will be denuded for cumulus testing and agree to the single blastocyst transfer. * Patients must be predicted good ovarian responders (AMH 1-4,7 ng/ml) with 7-18 follicles of minimum 10-11 mm on trigger day (oocyte retrieval minus 2 days (OR -2)) by ultrasound following ovarian stimulation with r-hFSH or r-hFSH with r-hLH in a Gonadotropin-releasing hormone (GnRH) antagonist protocol (starting dose recombinant Follicle Stimulating Hormone (rFSH) between 150-225 IU) * HCG trigger after stimulation (r-hCG) Exclusion Criteria: * Women with less than 7 or more than 18 follicles at Day -2 or -3 measured by ultrasound * Women with history of poor oocyte maturation or known maturation defect * Irregular menstrual cycle (\< 24 or \> 35 days) * BMI \< 17 or \> 33 * Smoking \> 10 cigarettes per day. * Known low ovarian response based on Bologna criteria * Combined use of urinary and recombinant gonadotropins in the current cycle * Patients with severe endometriosis ≥ III (AFS classification) * Polycystic ovary syndrome (PCOS), defined by revised criteria American Society for Reproductive Medicine (ASRM) European Society of Human Reproduction and Embryology (ESHRE) 2018 * Patient included in any other study * Patient scheduled for preimplantation genetic testing (PGT) * Testicular sperm extraction (TESE) or extreme oligo-astheno-teratozoospermia (OAT) with sperm count below 100.000/ml.